Table 1.
Non-Asian
|
Asian Indian
|
East Asian
|
||||
---|---|---|---|---|---|---|
LM25 (n=69) | G+L (n=61) | LM25 (n=53) | G+L (n=53) | LM25 (n=45) | G+L (n=44) | |
Mean age (SD), years | 58.62 (8.67) | 61.67 (8.45) | 55.15 (8.22) | 53.11 (8.62) | 57.20 (7.62) | 54.36 (9.07) |
Female sex, n (%) | 27 (39.1) | 24 (39.3) | 28 (52.8) | 28 (52.8) | 30 (66.7) | 24 (54.5) |
Mean duration of diabetes (SD), years | 12.61 (6.52) | 10.63 (6.32) | 9.51 (6.88) | 8.54 (4.41) | 10.03 (5.02) | 9.40 (4.43) |
Mean body weight (SD), kg | 84.03 (18.02) | 82.12 (14.82) | 65.96 (10.61) | 67.90 (10.18) | 67.79 (10.88) | 65.69 (10.37) |
Mean BMI (SD), kg/m2 | 29.56 (4.02) | 29.14 (3.82) | 26.09 (3.54) | 26.60 (3.87) | 25.62 (3.15) | 24.92 (2.81) |
Mean HbA1c (SD), % | 8.93 (1.02) | 8.85 (1.01) | 9.22 (1.09) | 9.29 (1.00) | 8.87 (0.92) | 8.82 (1.08) |
Sulfonylurea use, n (%)a | 69 (100.0) | 61 (100.0) | 53 (100.0) | 53 (100.0) | 42 (93.3) | 42 (95.5) |
Note:
At baseline, all patients in the full analysis set were on metformin.
Abbreviations: LM25, insulin lispro mix 25 (25% insulin lispro and 75% insulin lispro protamine suspension); G+L, glargine plus lispro; BMI, body mass index; HbA1c, glycated hemoglobin.